IMPROVED OVERALL SURVIVAL IN PATIENTS WITH ADVANCED SYSTEMIC MASTOCYTOSIS TREATED WITH AVAPRITINIB VERSUS REAL-WORLD THERAPY BASED ON MUTATION-ADJUSTED RISK SCORE STRATIFICATION (SIE 2026) - Oct 6, 2026 - Abstract #C032; Pres time: Sep 21, 2026; 03:40 PM - 05:10 PM; Location: HALL 3; P2 | "Conclusions. In patients with intermediate- or high-risk MARS, avapritinib treatment significantly improved OS ver- sus 1L midostaurin and 2L BAT, including in the SM-AHN subgroup, further characterizing the survival benefit of avapritinib."
Clinical • Metastases • Real-world • Real-world evidence • Hematological Disorders • Thrombocytopenia • ASXL1 • RUNX1 • SRSF2
|
|
M. Bonifacio1; A. Reiter2; J. Luebke2; J. Gotlib3; I. Alvarez-Twose4; D. Radia5; P. Bobbili6; A. Wang6; S. Dimitrijević7; O. Ponet7; E. Sullivan8; C. Tommasi9; J. Schwaab2; I. Galinsky10; C. Perkins3; W. Sperr11,12; P. Sriskandarajah5; M. Mohan6; A. Zhu6; M. Duh6; P. Valent11,12; D. Deangelo10; J. Rossignol13; O. Hermine13
|